Gene Therapy vs Cell Therapy — Rare Disease Deal Terms Comparison
Market Analysis
In rare disease, Gene Therapy and Cell Therapy represent two of the most actively transacted modalities. At Phase 2, Gene Therapy deals carry a median total deal value of $1.6B with $285M upfront, compared to $2.5B total value and $456M upfront for Cell Therapy. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Gene Therapy development milestones average $283M versus $441M for Cell Therapy. Commercial milestones are $682M for Gene Therapy and $1.1B for Cell Therapy. Royalty rates range from 7.8%-15.6% for Gene Therapy and 8.2%-16.4% for Cell Therapy.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Gene Therapy and Cell Therapy deal terms compare in rare disease?
Which modality commands higher royalty rates: Gene Therapy or Cell Therapy?
How do milestone structures differ between Gene Therapy and Cell Therapy?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.